top of page

Optimisation of paperboard can cut carbon footprint of pharmaceutical packaging by 60%

Packaging Solutions

Pharmaceutical product packaging accounts for a large part of manufacturers’ Scope 3 emissions, which consider, for example raw material production, manufacturing, and end of life disposal. According to Metsä Board studies, fresh fibre paperboard can notably reduce the carbon footprint of pharmaceutical packaging by optimising the paperboard in use.  


Assessments conducted by the company demonstrate the significant carbon footprint reductions that pharmaceutical manufacturers can achieve by switching from commonly used grades to Metsä Board fresh fibre paperboards. Switching from a solid bleached board (SBB) to the company’s folding boxboard can reduce the carbon footprint of packaging by over 50%, and replacing white lined chipboard (WLC) with folding boxboard can result in a 60% reduction or even higher. These assessments have been verified by IVL Swedish Environmental Research Institute. The technical background report and the verification statement are available on Metsä Board’s website.


The lower carbon footprint of these folding boxboards is due to the use of fossil free energy in their production and their lighter weight. However, despite the lighter weight, the company’s folding boxboards still retain the durability and functional properties of traditional heavier grades.


‘As a responsible materials supplier it is our job to provide pharma brand owners with transparent, unbiased information that helps them evaluate packaging materials to make better informed and sustainable choices to reduce their carbon footprint,’ said Anne Uusitalo, product safety and sustainability director.





Featured Posts
Recent Posts
bottom of page